Through research, innovation, and development, we’re elevating the standard of care through quality clinical evidence in partnership with clinicians, physicians, hospitals, and professional associations. Our clinical publications emphasize our ongoing commitment to improving procedure efficiency, and saving lives.
CAPTAIN randomized trial of TULSA vs. Radical Prostatectomy (NCT05027477)
CAPTAIN (A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants with Localized Prostate Cancer) is a prospective, multi-center randomized controlled trial aimed at comparing the safety and efficacy of the TULSA procedure (performed with the TULSA-PRO® system) with RP in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer.
Randomized control trial evaluating MRI-guided transurethral ultrasound ablation (TULSA) versus radical prostatectomy.
Klotz et al. European Association of Urology 2026 Congress
This presentation shows that at six month follow up, men with intermediate-risk prostate cancer had better preservation of both erectile function and urinary function with TULSA Procedure vs. surgery.
Perioperative outcomes from a randomized controlled trial comparing MRI-guided transurethral ultrasound ablation (TULSA) to robot-assisted radical prostatectomy (RARP).
Olivares et al. Journal of Clinical Oncology (2026)
This study has shown that men treated with the TULSA Procedure experience better preservation of urinary continence and erectile function, less pain after the procedure, faster recovery, fewer hospitalizations for complications, and a quicker return to normal activities and work compared with traditional prostate surgery.
TACT Multi-Center Trial with 5-year follow-up
The TACT (TULSA-PRO Ablation Clinical Trial) is a pivotal, prospective, multi-center trial that validated a novel, minimally invasive device for tissue ablation in 115 men with localized prostate cancer.
Pivotal study of MRI-guided transurethral ultrasound ablation (TULSA) of localized prostate cancer: 5-year follow up.
Eggener, et al. “Urologic Oncology (2024)
This study has shown that at five years after whole-gland ablation using TULSA-PRO in men with localized prostate cancer, 97% of patients maintained urinary control, 87% preserved erectile function and 78% required no additional cancer treatment.
Single-Center Trial in men with benign prostatic obstruction (NCT03350529)
Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study.
Viitala et al. BJU Int (2025)
This study has shown that for BPH patients who underwent the TULSA Procedure, at 12 months 96% of men discontinued BPH medications, 94% preserved erectile function and 100% maintained urinary control.